Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing StudyRia Garg, Mary A. De Vera, Eric C. Sayre et al.|Cancer Epidemiology Biomarkers & Prevention|2023Cited by 7
The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastasesS N Wong, Chi Kuen Wong, Chi‐Leung Chiang et al.|Annals of Oncology|2019Cited by 1
Figure S1 from Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing StudyRia Garg, Mary A. De Vera, Eric C. Sayre et al.|Unknown|2024Cited by 0
Figure S1 from Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing StudyRia Garg, Mary A. De Vera, Eric C. Sayre et al.|Unknown|2024Cited by 0
Table S2 from Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing StudyRia Garg, Mary A. De Vera, Eric C. Sayre et al.|Unknown|2024Cited by 0